Breast cancer Drug's hidden heart risks under the microscope

NCT ID NCT06781762

Recruiting now Knowledge-focused Sponsor: University of Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 40 postmenopausal women with hormone-positive breast cancer who are starting aromatase inhibitor therapy. Researchers will measure heart and blood vessel health, blood markers, body composition, and lifestyle factors over 6 months, comparing them to healthy women of the same age and weight. The goal is to understand why these drugs increase heart risks over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aromatase inhibitors
What this could lead to: If successful, this study could help doctors better monitor and prevent heart problems in breast cancer patients taking aromatase inhibitors.
What could go wrong: This is a small observational study with only 40 participants, so results may not apply to everyone. It does not test a new treatment, only measures existing side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer female breast carcinoma Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALES

Contacts and locations

Locations

University of Toronto
RECRUITING

Toronto, Ontario, M5S2C9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.